Ampio Pharmaceuticals commences Optina Stage II clinical trial for diabetic macular edema Ampio Pharmaceuticals, Inc. Diabetic macular edema is responsible for most vision loss in individuals with diabetes mellitus. Ampio Pharmaceuticals offers completed a formal agreement with St Michael’s Hospital, Toronto, Canada as your final stage for ethics board authorization which is expected within the next few days www.apcalis-sx.net http://apcalis-sx.net . Chief Scientific Officer, Dr. David Bar-Or added, ‘After accumulating in vitro and animal data, it is gratifying to begin with treating patients because of this debilitating disease.’ Diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in approximately one third of patients a decade after the onset of diabetes and are rapidly growing factors behind blindness worldwide.

A biotechnology pioneer since 1980, Amgen was among the first companies to understand the new science’s promise by bringing safe, effective medicines from laboratory to manufacturing plant to individual. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to significantly improve people’s lives. About Micromet, Inc. Micromet is usually a biopharmaceutical company focused on the discovery, commercialization and development of innovative antibody-based therapies for the treatment of cancer.

Other entries from category "clinical":

Random entries